1ABBV / AbbVie Inc. (BIT) - Forecast, Price Target, Estimates, Predictions

AbbVie Inc.
IT ˙ BIT ˙ US00287Y1091
€179.00 0.00 (0.00%)
2025-09-04
SHARE PRICE
Projected Stock Price
€188.53 ↑5.33%

Estimated share price by August 22, 2026.

Projected Revenue

76,302  MM ↑394.73%

Estimated quarterly revenue by June 30, 2026.

Projected Earnings Per Share

4.21 ↑702.57%

Estimated quarterly earnings by December 31, 2026.

Price Target

The average one-year price target for AbbVie Inc. is €188.53. The forecasts range from a low of €146.29 to a high of €228.13.

Update Frequency: Monthly

Record Date Projection Date High Low Median Average
2025-08-22 2026-08-22 228.13 146.29 186.85 188.53
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for AbbVie Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2024-07-19 BMO Capital Outperform Outperform Maintains
2024-07-11 Morgan Stanley Overweight Overweight Maintains
2024-07-09 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-02 Piper Sandler Overweight Overweight Maintains
2024-06-20 Cantor Fitzgerald Overweight Overweight Reiterate
2024-06-18 Piper Sandler Overweight Overweight Maintains
2024-06-05 HSBC Hold Buy Upgrade
2024-05-17 Cantor Fitzgerald Overweight Initiate
2024-04-29 Barclays Overweight Overweight Maintains
2024-04-29 BMO Capital Outperform Outperform Maintains
2024-03-27 Barclays Overweight Overweight Maintains
2024-03-22 Guggenheim Buy Buy Maintains
2024-02-06 Raymond James Outperform Maintains
2024-02-06 Truist Securities Buy Buy Maintains
2024-02-05 BMO Capital Outperform Outperform Maintains
2024-02-05 Raymond James Outperform Outperform Maintains
2024-02-05 Barclays Overweight Overweight Maintains
2024-01-29 William Blair Market Perform Outperform Upgrade
2024-01-23 Barclays Overweight Overweight Maintains
2023-12-18 HSBC Buy Hold Downgrade
2023-12-11 Goldman Sachs Neutral Buy Upgrade
2023-12-01 Raymond James Outperform Outperform Maintains
2023-11-09 Deutsche Bank Hold Initiate
2023-10-30 Morgan Stanley Overweight Overweight Maintains
2023-10-30 Barclays Equal-Weight Overweight Upgrade
2023-10-11 Morgan Stanley Overweight Overweight Maintains
2023-09-29 Raymond James Outperform Initiate
2023-07-28 Piper Sandler Overweight Overweight Maintains
2023-07-25 William Blair Market Perform Initiate
2023-07-14 HSBC Buy Initiate
2023-07-11 Morgan Stanley Overweight Overweight Reiterate
2023-04-28 Guggenheim Buy Maintains
2023-04-28 Morgan Stanley Overweight Maintains
2023-04-28 Wells Fargo Overweight Maintains
2023-04-10 Morgan Stanley Overweight Maintains
2023-04-05 Argus Research Buy Hold Downgrade
2023-03-01 Guggenheim Buy Initiate
2023-02-22 Wolfe Research Outperform Peer Perform Downgrade
2023-02-10 SVB Leerink Underperform Market Perform Upgrade
2023-02-10 Atlantic Equities Neutral Maintains
2023-02-10 Morgan Stanley Overweight Maintains
2023-02-10 Piper Sandler Overweight Maintains
2023-02-06 BMO Capital Outperform Maintains
2023-01-17 Piper Sandler Overweight Maintains
2022-12-06 Morgan Stanley Overweight Maintains
2022-11-18 Credit Suisse Outperform Initiate
2022-11-08 Societe Generale Buy Hold Downgrade
2022-10-31 Atlantic Equities Neutral Maintains
2022-10-31 BMO Capital Outperform Maintains
2022-10-31 Morgan Stanley Overweight Maintains
2022-10-31 Barclays Equal-Weight Maintains
2022-10-11 Morgan Stanley Overweight Maintains
2022-09-30 SVB Leerink Underperform Maintains
2022-08-24 Argus Research Buy Maintains
2022-08-01 UBS Neutral Maintains
2022-08-01 Morgan Stanley Overweight Maintains
2022-08-01 Barclays Equal-Weight Maintains
2022-08-01 Atlantic Equities Neutral Maintains
2022-07-08 Morgan Stanley Overweight Maintains
2022-05-23 SVB Leerink Underperform Initiate
2022-05-02 Morgan Stanley Overweight Maintains
2022-05-02 Wells Fargo Overweight Maintains
2022-04-25 BMO Capital Outperform Maintains
2022-04-12 Barclays Equal-Weight Maintains
2022-04-12 Goldman Sachs Neutral Maintains
2022-04-06 Morgan Stanley Overweight Maintains
2022-02-28 UBS Buy Neutral Downgrade
2022-02-04 Mizuho Buy Maintains
2022-02-03 Barclays Equal-Weight Maintains
2022-01-24 Morgan Stanley Overweight Maintains
2022-01-20 Barclays Equal-Weight Maintains
2022-01-12 BMO Capital Outperform Maintains
2022-01-05 Mizuho Buy Maintains
2021-12-17 Goldman Sachs Neutral Initiate
2021-12-09 Wells Fargo Overweight Initiate
2021-11-23 Societe Generale Hold Buy Upgrade
2021-11-01 Barclays Equal-Weight Maintains
2021-11-01 Morgan Stanley Overweight Maintains
2021-11-01 SVB Leerink Outperform Maintains
2021-08-20 SVB Leerink Outperform Maintains
2021-08-02 Mizuho Buy Maintains
2021-08-02 SVB Leerink Outperform Maintains
2021-05-03 BMO Capital Outperform Maintains
2021-03-30 SVB Leerink Outperform Maintains
2021-02-04 SVB Leerink Outperform Maintains
2021-01-28 Morgan Stanley Overweight Maintains
2020-12-16 SVB Leerink Outperform Maintains
2020-11-30 Morgan Stanley Overweight Maintains
2020-11-18 BMO Capital Outperform Initiate
2020-11-10 Bernstein Outperform Initiate
2020-11-02 SVB Leerink Outperform Maintains
2020-10-23 Truist Securities Buy Initiate
2020-10-16 JP Morgan Overweight Maintains
2020-09-29 Berenberg Hold Initiate
2020-09-02 Citigroup Buy Maintains
2020-08-20 Morgan Stanley Overweight Maintains
2020-08-03 Mizuho Buy Maintains
2020-08-03 RBC Capital Outperform Maintains
2020-06-23 Atlantic Equities Neutral Overweight Upgrade
2020-06-02 Argus Research Hold Buy Upgrade
2020-05-18 B of A Securities Neutral Reiterate
2020-05-12 JP Morgan Neutral Overweight Upgrade
2020-05-11 Morgan Stanley Overweight Reiterate
2020-05-11 SVB Leerink Outperform Maintains
2020-05-04 SVB Leerink Outperform Maintains
2020-04-20 RBC Capital Sector Perform Outperform Upgrade
2020-04-13 UBS Buy Maintains
2020-03-23 Societe Generale Buy Hold Downgrade
2020-02-27 Barclays Equal-Weight Initiate
2020-02-18 Cowen & Co. Outperform Maintains
2020-02-10 Mizuho Buy Maintains
2020-02-06 Mizuho Buy Initiate
2019-12-26 Cowen & Co. Outperform Maintains
2019-11-20 Citi Buy Maintains
2019-11-19 UBS Buy Maintains
2019-09-26 Citigroup Neutral Buy Upgrade
2019-09-12 UBS Neutral Buy Upgrade
2019-09-04 Piper Jaffray Overweight Maintains
2019-08-20 Piper Jaffray Neutral Overweight Upgrade
2019-06-26 SVB Leerink Market Perform Outperform Upgrade
2019-05-28 Goldman Sachs Neutral Initiate
2019-04-29 BMO Capital Underperformer Market Perform Upgrade
2019-01-03 Bank of America Buy Neutral Downgrade
2018-12-26 Standpoint Research Buy Initiate
2018-11-06 Argus Buy Buy Maintains
2018-11-05 BMO Capital Underperform Underperform Maintains
2018-10-04 Bank of America Buy Buy Maintains
2018-08-22 Bank of America Buy Buy Maintains
2018-07-30 Bank of America Buy Buy Maintains
2018-07-12 Berenberg Hold Initiate
2018-06-11 Argus Buy Buy Maintains
2018-06-01 PiperJaffray Overweight Neutral Downgrade
2018-05-30 Credit Suisse Neutral Underperform Downgrade
2018-05-23 BMO Capital Underperform Underperform Maintains
2018-04-30 Morgan Stanley Equal-Weight Equal-Weight Maintains
2018-04-27 Credit Suisse Neutral Neutral Maintains
2018-04-05 Barclays Equal-Weight Equal-Weight Maintains
2018-03-23 BMO Capital Underperform Underperform Maintains
2018-02-02 Argus Buy Maintains
2018-01-30 Morgan Stanley Equal-Weight Equal-Weight Maintains
2018-01-30 BMO Capital Market Perform Underperform Downgrade
2018-01-29 Leerink Swann Outperform Market Perform Downgrade
2017-11-16 BMO Capital Market Perform Maintains
2017-10-30 Leerink Swann Outperform Maintains
2017-10-13 Barclays Equal-Weight Maintains
2017-10-13 UBS Neutral Maintains
2017-10-11 Cowen & Co. Market Perform Outperform Upgrade
2017-10-05 Leerink Swann Outperform Maintains
2017-10-02 Leerink Swann Outperform Maintains
2017-09-25 UBS Buy Neutral Downgrade
2017-09-15 Jefferies Buy Maintains
2017-08-17 Evercore ISI Group Outperform Initiate
2017-07-17 Jefferies Buy Maintains
2017-07-17 Deutsche Bank Hold Maintains
2017-03-10 Goldman Sachs Buy Buy Maintains
2016-11-28 Citigroup Buy Neutral Downgrade
2016-10-31 Credit Suisse Outperform Neutral Downgrade
2016-10-18 Leerink Swann Market Perform Initiate
2016-09-08 JP Morgan Overweight Neutral Downgrade
2016-09-02 Raymond James Outperform Initiate
2016-06-10 BMO Capital Outperform Market Perform Downgrade
2016-06-08 Morgan Stanley Overweight Equal-Weight Downgrade
2016-06-06 Cowen & Co. Outperform Market Perform Downgrade
2016-04-06 Societe Generale Sell Initiate
2016-03-15 Deutsche Bank Hold Initiate
2016-03-07 Goldman Sachs Buy Maintains
2016-02-23 Citigroup Neutral Buy Upgrade
2016-02-05 William Blair Outperform Initiate
2016-01-14 Jefferies Buy Maintains
2015-12-18 Atlantic Equities Neutral Initiate
2015-12-01 Barclays Overweight Equal-Weight Downgrade
2015-11-02 Morgan Stanley Equal-Weight Overweight Upgrade
2015-07-29 Deutsche Bank Buy Maintains
2015-07-22 SunTrust Robinson Humphrey Buy Initiate
2015-06-16 PiperJaffray Overweight Initiate
2015-06-08 Jefferies Buy Maintains
2015-04-24 BMO Capital Outperform Maintains
2015-04-13 BMO Capital Market Perform Outperform Upgrade
2015-02-09 Citigroup Sell Initiate
2015-02-03 Jefferies Buy Maintains
2015-01-16 Barclays Overweight Maintains
2015-01-15 Jefferies Buy Maintains
2015-01-09 Bank of America Buy Neutral Downgrade
2014-12-11 Morgan Stanley Overweight Equal-Weight Downgrade
2014-12-04 Jefferies Buy Maintains
2014-11-14 Deutsche Bank Outperform Initiate
2014-11-04 Jefferies Buy Maintains
2014-11-03 JP Morgan Overweight Maintains
2014-10-17 ISI Group Buy Initiate
2014-10-02 Guggenheim Buy Initiate
2014-08-06 Credit Suisse Outperform Maintains
2014-07-28 UBS Neutral Buy Upgrade
2014-07-18 Jefferies Buy Maintains
2014-07-14 Jefferies Buy Maintains
2014-07-02 Barclays Equal-weight Overweight Upgrade
2014-06-20 Credit Suisse Outperform Maintains
2014-05-07 Morgan Stanley Equal-weight Overweight Upgrade
2014-04-24 Bank of America Buy Maintains
2014-04-14 Jefferies Buy Maintains
2014-02-21 Bank of America Buy Maintains
2014-01-27 Morgan Stanley Equal-Weight Maintains
2013-12-31 Bank of America Buy Maintains
2013-12-19 Morgan Stanley Overweight Equal-weight Downgrade
2013-10-25 BMO Capital Market Perform Outperform Upgrade
2013-10-08 Credit Suisse Outperform Initiate
2013-08-12 Argus Buy Initiate
2013-06-07 Jefferies Buy Maintains
2013-05-28 Jefferies Buy Maintains
2013-05-15 Cowen & Co. Outperform Initiate
2013-04-29 BMO Capital Market Perform Maintains
2013-04-22 Morgan Stanley Equal-Weight Overweight Upgrade
2013-04-10 Jefferies Buy Maintains
2013-04-10 UBS Neutral Maintains
2013-04-09 Goldman Sachs Buy Maintains
2013-04-05 BMO Capital Market Perform Maintains
2013-04-01 BMO Capital Outperform Market Perform Downgrade
2013-03-11 Bank of America Buy Maintains
2024-08-12 Morgan Stanley Overweight Overweight Maintains
2025-01-28 Citigroup Buy Buy Maintains
2024-08-05 Cantor Fitzgerald Overweight Overweight Reiterate
2024-11-12 BMO Capital Outperform Outperform Maintains
2024-11-12 Citigroup Buy Buy Maintains
2024-11-12 Morgan Stanley Overweight Overweight Maintains
2024-07-26 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-26 Truist Securities Buy Buy Reiterate
2024-07-26 Wells Fargo Overweight Overweight Maintains
2024-07-26 Barclays Overweight Overweight Maintains
2024-10-25 Citigroup Buy Buy Maintains
2024-10-18 B of A Securities Neutral Neutral Maintains
2024-10-17 BMO Capital Outperform Outperform Maintains
2024-10-17 Bernstein Market Perform Initiate
2024-10-10 Truist Securities Buy Buy Maintains
2024-10-09 UBS Neutral Neutral Maintains
2024-10-07 TD Cowen Buy Buy Maintains
2024-10-07 Barclays Overweight Overweight Maintains
2024-11-06 Guggenheim Buy Buy Maintains
2024-11-04 Argus Research Hold Buy Upgrade
2024-10-31 Citigroup Buy Buy Maintains
2024-10-31 UBS Neutral Neutral Maintains
2024-10-31 Morgan Stanley Overweight Overweight Maintains
2025-04-17 Guggenheim Buy Buy Reiterate
2025-01-08 Truist Securities Buy Buy Maintains
2024-08-23 Piper Sandler Overweight Overweight Maintains
2024-12-10 B of A Securities Neutral Reiterate
2024-11-22 Leerink Partners Market Perform Outperform Upgrade
2024-11-15 Wolfe Research Outperform Initiate
2024-11-13 JP Morgan Overweight Overweight Maintains
2025-02-03 Wells Fargo Overweight Overweight Maintains
2025-02-03 UBS Neutral Neutral Maintains
2025-02-03 Truist Securities Buy Buy Maintains
2025-02-03 Citigroup Buy Buy Maintains
2025-02-03 Morgan Stanley Overweight Overweight Maintains
2025-02-03 BMO Capital Outperform Outperform Maintains
2025-02-03 Guggenheim Buy Buy Maintains
2025-02-03 Raymond James Outperform Outperform Reiterate
2025-05-14 Citigroup Buy Neutral Downgrade
2025-03-04 B of A Securities Neutral Neutral Maintains
2024-12-17 Piper Sandler Overweight Overweight Maintains
2025-04-09 Morgan Stanley Overweight Overweight Maintains
2025-03-05 Wells Fargo Overweight Overweight Maintains
2025-04-22 Cantor Fitzgerald Overweight Initiate
2025-04-29 Guggenheim Buy Buy Maintains
2025-04-28 Morgan Stanley Overweight Overweight Maintains
2025-04-28 Evercore ISI Group Outperform Outperform Maintains
2025-08-01 Guggenheim Buy Buy Maintains
2025-08-01 Morgan Stanley Overweight Overweight Maintains
2025-08-01 Raymond James Outperform Outperform Maintains
Revenue Estimates

The forecasted annual revenue of AbbVie Inc. in 2031-12-31 is 75,636MM. )

Understanding a company’s revenue history gives investors a snapshot of its potential growth. Revenue growth is a solid predictor of earnings (or profit) growth. A company that can increase its revenue while keeping its operating costs constant has more available capital to reinvest into its business or return to shareholders through dividends or share buybacks.

However, investors should be careful before investing in a company that is growing revenue but showing declining earnings or is unprofitable. In some cases, this is simply a case of a young company that is still in an early growth phase. But if this is a mature company, it can indicate that other fundamental problems exist.

How to Interpret Revenue Estimates?

Fintel gives you revenue projections for stocks that cover 10 years between 2020 and 2030. Although past performance does not guarantee future results, you can be more confident in your decision to buy or sell a stock when you see a company with revenue that has a track record of increasing its revenue.

Update Frequency: Quarterly

Date Revenue Average Quarterly (MM) Number of Analysts (Quarterly) Revenue Average Annually (MM) Number of Analysts (Annually)
2025-09-30 14,127 3 -- --
2025-12-31 14,387 3 57,074 23
2026-03-31 73,382 3 -- --
2026-06-30 76,302 3 -- --
2026-12-31 -- -- 59,549 16
2027-12-31 -- -- 61,503 13
2028-12-31 -- -- 64,175 9
2029-12-31 -- -- 64,593 9
2030-12-31 -- -- 64,196 9
2031-12-31 -- -- 75,636 10
Earnings Estimates

The forecasted annual earnings of AbbVie Inc. in 2032-12-31 is 20.83 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 2.91 3 -- --
2025-12-31 3.00 3 12.32 23
2026-03-31 16.42 3 -- --
2026-06-30 17.58 3 -- --
2026-09-30 3.95 3 -- --
2026-12-31 4.21 3 13.15 15
2027-12-31 -- -- 13.94 11
2028-12-31 -- -- 15.08 9
2029-12-31 -- -- 15.41 9
2030-12-31 -- -- 15.46 9
2031-12-31 -- -- 18.05 8
2032-12-31 -- -- 20.83 6
EBITDA Estimates

The forecasted annual EBITDA of AbbVie Inc. in 2028-12-31 is 38,036MM.

EBIDTA is an acronym that stands for earnings before interest, taxes, depreciation, and amortization. Analysts and investors pay attention to EBITDA because it strips out items that a company must report on its balance sheet but doesn’t significantly impact its business. Here’s an explanation of what that means for each part of the acronym:

Interest: Loan interest and earnings are subject to change based on a company’s financial strategy and, in any event, are not part of its core activities.

Taxes: Taxes are affected by governmental policy that can distort a company’s perceived profitability.

Depreciation: This accounts for the expected depreciation on tangible assets and immaterial goods from company investments. But since these investments may ultimately increase a company’s efficiency and profit potential, they aren’t a good indicator of a company’s current profitability.

Amortization: This shows the gradual writing off of the initial cost of an asset. It differs from depreciation because it is typically used with intangible assets such as intellectual property (e.g., patents, copyrights, etc.)

EBITDA vs. Net Income

Net income is the profit a company has left over after covering its operating expenses. However, net income includes the items that EBITDA excludes. That’s why most analysts prefer EBITDA because it better reflects the health of a company’s core business.

Update Frequency: Quarterly

Date EBITDA Average (MM Quarterly) Number of Analysts (Quarterly) EBITDA Average (MM Annually) Number of Analysts (Annually)
2025-12-31
2026-12-31
2027-12-31
2028-12-31
EBIT Estimates

The forecasted annual EBIT of AbbVie Inc. in 2028-12-31 is 34,143MM.

EBIT is an acronym that stands for earnings before interest and taxes. Analysts use EBIT to measure a company’s performance because it strips out tax expenses and the costs of the capital structure influencing profit. These don’t significantly impact a company’s business.

Interest: Loan interest and earnings are subject to change based on a company’s financial strategy and, in any event, are not part of its core activities.

Taxes: Taxes are affected by governmental policy that can distort a company’s perceived profitability.

NOTE: EBIT is sometimes synonymous with operating income. However, in some cases, operating income doesn’t include gains or losses from non-core activities.

EBIT vs. EBITDA

EBITDA also strips out depreciation and amortization from a company’s earnings:

Depreciation: This accounts for the expected depreciation on tangible assets and immaterial goods from company investments. But since these investments may ultimately increase a company’s efficiency and profit potential, they aren’t a good indicator of a company’s current profitability.

Amortization: This shows the gradual writing off of the initial cost of an asset. It differs from depreciation because it is typically used with intangible assets such as intellectual property (e.g., patents, copyrights, etc.)

Update Frequency: Quarterly

Date EBIT Average (MM Quarterly) Number of Analysts (Quarterly) EBIT Average (MM Annually) Number of Analysts (Annually)
2025-09-30
2025-12-31
2026-12-31
2027-12-31
2028-12-31
Other Listings
PE:ABBV
BG:4AB
MX:ABBV
US:ABBV $212.56
GB:4ABD
GB:0QCV $213.00
AT:ABBV
CL:ABBVCL
DE:4AB €180.40
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista